Prostate Cancer Diagnostics Market size was valued at USD 5 billion in 2024 and is projected to reach USD 19.4 billion by the end of 2037, rising at a CAGR of 11% during the forecast period, i.e., 2025-2037. In 2025, the industry size of prostate cancer diagnostics is evaluated at USD 5.5 billion.
The prostate cancer diagnostics market is expected to witness steady growth due to the increasing demand for advanced diagnostic tools, stimulated by increased incidence rates of prostate cancer and an expanding geriatric population. Given the importance of early detection, healthcare providers continue to invest in new technologies while making diagnostic services more widely accessible. For example, Cortechs.ai launched OnQ Prostate in May 2024 which is a software that's been cleared by the FDA to detect prostate cancer. Such advancements, along with a strong emphasis on precision diagnosis, coupled with government-funded initiatives that advance screening capabilities and create public awareness regarding health, boost market growth.
The prostate cancer diagnostics industry is being actively supported by governments worldwide through funds and awareness-raising, especially for early detection and preventive care. Many governmental health departments report their increased investments in cancer screening programs across less privileged regions. In 2024, the U.S. government declared funding of USD 9 million to be invested in August to increase access to cancer screening across health centers in various regions. This governmental support is instrumental in widening the scope of diagnostics of prostate cancer by providing wider access to advanced tools and increasing the rate of early detection, thus improving patients' outcomes.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
11% |
|
Base Year Market Size (2024) |
USD 5 billion |
|
Forecast Year Market Size (2037) |
USD 19.4 billion |
|
Regional Scope |
|
Test Type (Diagnostics Tests, Imaging Tests)
The diagnostic tests segment is poised to capture around 65% prostate cancer diagnostics market share by the end of 2037 due to innovation in biomarker tests and mounting emphasis on early diagnosis. Diagnostic tests allow for accurate and less invasive detection of prostate cancer, thus addressing the growing need for accessible prostate cancer screening. In July 2023, Quest Diagnostics introduced AmeriPath's biomarker test for prostate cancer, underlining the dependency on diagnostic tests for early detection. Such product launches indicate the growth prospects of the segment during the forecast period.
Cancer Type (Prostatic Adenocarcinoma, Small Cell Carcinoma, Other Prostate Cancer Types)
By the end of 2037, prostatic adenocarcinoma segment is estimated to account for more than 76% prostate cancer diagnostics market share, as it is among the most prevalent types of prostate cancer. Since prostatic adenocarcinoma has a high incidence worldwide, the demand for diagnostic tools specifically meant for tracking and diagnosis of these types of cancers increases. In August 2023, Myriad Genetics introduced Absolute Risk Reduction for the Prolaris Prostate Cancer Prognostic Test, aimed at helping patients with prostatic adenocarcinoma make more informed decisions regarding their treatment options. This approach by companies to offer diagnostics in prostatic adenocarcinoma offers continued growth in the market.
Our in-depth analysis of the prostate cancer diagnostics market includes the following segments:
|
Test Type |
|
|
Cancer Type |
|
|
End use |
|
North America Market Analysis
North America prostate cancer diagnostics market is estimated to dominate revenue share of around 34.5% by the end of 2037, driven by advanced healthcare infrastructure, coupled with high incidence rates for cancer and strong support from the government. Furthermore, increased public awareness and proactive screening methods have made North America a lucrative market for companies in the prostate cancer diagnostics market. The U.S. and Canada continue to lead in North America, holding investment prospects for new players.
The U.S. prostate cancer diagnostics market demonstrates strong adoption of advanced diagnostic modalities since the country carries out large-scale screening programs and has substantial funding from the government. For example, Lantheus Holdings announced revenues of over USD 150 million for PYLARIFY, its leading PSMA PET imaging test for prostate cancer, in March 2024. Strong revenue indicates high demand for advanced diagnostic solutions in the U.S., driven by early diagnosis and precision medicine.
Canada healthcare system is becoming another leading adopter of advanced diagnostics due to governmental approvals for new technologies in cancer screening. For example, in May 2023, Health Canada approved the PSMA PET imaging agent known as Illuccix for the diagnostics of prostate cancer. Therefore, this highlights that the country is committed to promoting innovative healthcare solutions. This approval underlines that Canada is proactive in the adoption of cutting-edge diagnostic tools, hence driving North America prostate cancer diagnostics market.
Asia Pacific Market Analysis
Asia Pacific prostate cancer diagnostics market is anticipated to observe growth of around 10.5% between 2024 and 2037. This is owing to increased investments by governments in health infrastructure and an increased focus on early detection of cancer. Furthermore, an increasing geriatric population and better access to healthcare services are opening up new avenues for diagnostics providers in the region.
India prostate cancer diagnostics market is rising at a steady pace, with the government investing more in cancer care and making greater efforts to raise public health awareness. For example, the Assam government announced in November 2023 that it would invest INR 135 crore in the Assam Cancer Care Foundation to construct ten cancer hospitals, which would increase access to diagnostics. Thus, the determination of India to counter the rising influence of cancer with better health facilities further promotes market growth.
China prostate cancer diagnostics market growth is propelled by the government’s initiatives to improve access to healthcare, along with agreements with overseas companies for the provision of diagnostics. For example, in October 2023, a collaboration between Sinotau Pharmaceutical Group and Blue Earth Diagnostics introduced a new imaging agent in China used in diagnosing prostate cancer. The collaboration represents the country's commitment to new diagnostic solutions, driving the prostate cancer diagnostics market growth through 2037.
Leading companies operating in the prostate cancer diagnostics market include Abbott Laboratories, GE Healthcare Technologies Inc., Glycanostics Ltd., AdvaCare Pharma, Beckman Coulter, Inc., Becton, Dickinson and Company, bioMérieux, and F. Hoffmann-La Roche Ltd. Major players are investing in research and development, expanding partnerships, and focusing on product launches to strengthen their market presence, especially as demand for precision medicine grows. Furthermore, these players are making investments in research and development, further expanding the series of partnerships, focusing on product launches, and strengthening their presence in the market.
For example, Proteomedix AG and Blue Water Biotech Inc. merged in December 2023 to form Onconetix Inc., which integrates products for prostate cancer diagnosis and therapy. This trend in the industry reflects the consolidation and collaboration to realize comprehensive diagnostic portfolios. The enlarged capabilities the merger has brought to Onconetix Inc. speak volumes about the competitive outlook that sees increasing interest in expanding product offerings by companies to leverage their synergies by entering alliances. Such moves by players address diverse needs within prostate cancer diagnostics for early detection and to yield better patient care outcomes.
Here are some leading players in the prostate cancer diagnostics market:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?